NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, has been preliminarily approved by the State of NJ to sell approximately $300,000 of its Fiscal Year 2008 net operating tax losses (NOL) and research tax credits through the NJ Economic Development Authority (NJEDA) pursuant to the rules, regulations and stipulations set forth by the NJ program. This transaction is expected to be concluded in January 2010.
